| Ytd | 2.12% | |
| 1y | 119.62% |
| Open | 4.64 | Prev Close | 4.67 | Low | 4.06 | High | 4.70 | Mkt Cap | 385.30M |
| Vol | 806.77K | Avg Vol | 592.69K | EPS | -2.07 | P/E | N/A | Forward P/E | -1.23 |
| Beta | 0.39 | Short Ratio | 8.64 | Inst. Own | 67.66% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 4.09 | 200-d Avg | 3.80 | 1yr Est | 3.05 |
XFOR News
BOSTON, July 01, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on im
Leerink Partners analyst Thomas Smith initiates coverage on X4 Pharmaceuticals (NASDAQ:XFOR) with
X4 Pharmaceuticals (NASDAQ:XFOR) reported quarterly losses of $(0.16) per share which beat the analy
- European Commercialization will be Led by X4 Pharmaceuticals' Partner, Norgine - - Global, Piv
X4 Pharmaceuticals (NASDAQ:XFOR) reported quarterly losses of $(0.22) per share which beat the analy
Guggenheim analyst Michael Schmidt initiates coverage on X4 Pharmaceuticals (NASDAQ:XFOR) with a
Stifel analyst James Condulis maintains X4 Pharmaceuticals (NASDAQ:XFOR) with a Buy and raises th
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains X4 Pharmaceuticals (NASDAQ:XFOR)
X4 Pharmaceuticals (NASDAQ:XFOR) reported quarterly losses of $(0.69) per share which beat the analy
And, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 700,000 sha
X4 Pharmaceuticals (NASDAQ:XFOR) ("X4" or the "Company"), a company driven to improv
Organizational restructuring including a 50% reduction in workforce that is anticipated to result in
Stifel analyst Stephen Willey maintains X4 Pharmaceuticals (NASDAQ:XFOR) with a Buy and lowers th
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains X4 Pharmaceuticals (NASDAQ:XFOR)
$60 million PIPE financing led by Coastlands Capital, Bain Capital Life Sciences and New Enterprise
https://www.sec.gov/ix?doc=/Archives/edgar/data/1501697/000162828025032627/xfor-20250623.htm
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains X4 Pharmaceuticals (NASDAQ:XFOR)
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates X4 Pharmaceuticals (NASDAQ:XFOR
Cantor Fitzgerald analyst Kristen Kluska reiterates X4 Pharmaceuticals (NASDAQ:XFOR) with a Overw
X4 Pharmaceuticals (NASDAQ:XFOR) reported quarterly losses of $(0.20) per share which missed the ana
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates X4 Pharmaceuticals (NASDAQ:XFOR
X4 Pharmaceuticals (NASDAQ:XFOR), a company driven to improve the lives of people with rare diseases
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates X4 Pharmaceuticals (NASDAQ:XFOR
X4 to receive a €28.5 million upfront payment and up to €226 million in potential regulatory and com
X4 Pharmaceuticals (NASDAQ:XFOR), a company driven to improve the lives of people with rare diseases
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains X4 Pharmaceuticals (NASDAQ:XFOR)
Stifel analyst Stephen Willey maintains X4 Pharmaceuticals (NASDAQ:XFOR) with a Buy and lowers th
X4 had $135.8 million in cash, cash equivalents, restricted cash, and short-term marketable securiti